Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
09:36
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
FAQs
   
Discussion forum - 13th International Conference on Malignant Lymphoma
    Topic - Aggressive B-cell lymphoma

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma  Mathias Witzens-Harig 1      6/10/2015 6:00:00 PM  
Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies  Arnon Kater 1      6/9/2015 5:18:00 PM  
Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi  ANNALISA CHIAPPELLA 1      6/9/2015 12:26:00 AM  
Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS)  Annarita Conconi 1      6/9/2015 12:02:00 AM  
PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS  Caroline Faes 1      6/8/2015 10:22:00 PM  
Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs  BROSÉUS Julien 1      6/8/2015 10:17:00 PM  
Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution  Darius Juskevicius 1      6/8/2015 8:19:00 PM  
Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL- Interim Results from a Nordic Phase II Study  Sirpa Leppa 1      6/8/2015 8:07:00 PM  
Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients  Salma Afifi 1      6/8/2015 7:03:00 PM  
Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study.  Olivier Casasnovas 1      6/8/2015 5:36:00 PM  
Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP  Olivier Casasnovas 1      6/8/2015 4:33:00 PM  
RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP  SARA ALONSO ALVAREZ 1      6/7/2015 10:03:00 PM  
BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO  MIRIAM LÓPEZ-PARRA 1      6/7/2015 9:29:00 PM  
Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype  Michael Gilbertson 1      6/7/2015 8:25:00 AM  
Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model  Roopesh Kansara 1      6/6/2015 5:10:00 PM  
Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study  Emmanuel Gyan 1      6/6/2015 3:44:00 PM  
Prognostic impact of immunohistological profiling in primary CNS lymphoma  Stephan Kreher 1      6/6/2015 12:53:00 PM  
Cell of origin is not associated with survival after DLBCL relapse  Umar Farooq 1      6/5/2015 10:05:00 PM  
Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL  Alexandra Valera 1      6/5/2015 8:22:00 AM  
Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma  Lena Modvig 1      6/4/2015 10:36:00 PM  
Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance)  patrick johnston 1      6/4/2015 8:55:00 PM  
NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy  Alexander Deutsch 1      6/2/2015 7:18:00 AM  
Analysis of double-hit lymphoma cases by genetic subtype  Chadi Nabhan 1      6/2/2015 4:37:00 AM  
The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP  Diego Villa 1      5/30/2015 1:16:00 AM  
MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome  Jordina Rovira Sole 1      5/25/2015 3:31:00 PM  
MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma  Ting-Xun Lu 1      5/23/2015 1:23:00 PM  
       




Most viewed poster for this congress
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center

Poster most viewed in this topic
Poster: 154
Visits: 188
Title: NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy
Authors: Alexander Deutsch ,
Centre: Clinical Devision of Hematology


 




PosterSessionOnline
Logo Draft
 
Logo Cert